106 related articles for article (PubMed ID: 38733986)
1. Age-specific induction of mutant p53 drives clonal hematopoiesis and acute myeloid leukemia in adult mice.
Pourebrahim R; Montoya RH; Akiyama H; Ostermann L; Khazaei S; Muftuoglu M; Baran N; Zhao R; Lesluyes T; Liu B; Khoury JD; Gagea M; Van Loo P; Andreeff M
Cell Rep Med; 2024 May; 5(5):101558. PubMed ID: 38733986
[TBL] [Abstract][Full Text] [Related]
2. Role of p53 in regulation of hematopoiesis in health and disease.
Barajas S; Cai W; Liu Y
Curr Opin Hematol; 2022 Jul; 29(4):194-200. PubMed ID: 35787548
[TBL] [Abstract][Full Text] [Related]
3. AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.
Yan B; Claxton D; Huang S; Qiu Y
Exp Hematol; 2020 Jul; 87():13-19. PubMed ID: 32569759
[TBL] [Abstract][Full Text] [Related]
4. p53 involvement in clonal hematopoiesis of indeterminate potential.
Chen S; Liu Y
Curr Opin Hematol; 2019 Jul; 26(4):235-240. PubMed ID: 31045645
[TBL] [Abstract][Full Text] [Related]
5. A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1.
Loizou E; Banito A; Livshits G; Ho YJ; Koche RP; Sánchez-Rivera FJ; Mayle A; Chen CC; Kinalis S; Bagger FO; Kastenhuber ER; Durham BH; Lowe SW
Cancer Discov; 2019 Jul; 9(7):962-979. PubMed ID: 31068365
[TBL] [Abstract][Full Text] [Related]
6. Clonal Hematopoiesis and therapy related MDS/AML.
Desai P; Roboz GJ
Best Pract Res Clin Haematol; 2019 Mar; 32(1):13-23. PubMed ID: 30927970
[TBL] [Abstract][Full Text] [Related]
7. Mdm2/p53 levels in bone marrow mesenchymal stromal cells are essential for maintaining the hematopoietic niche in response to DNA damage.
Pourebrahim R; Heinz Montoya R; Alaniz Z; Ostermann L; Lin PP; Liu B; Ayoub E; Burks JK; Andreeff M
Cell Death Dis; 2023 Jun; 14(6):371. PubMed ID: 37353528
[TBL] [Abstract][Full Text] [Related]
8. Mosaic loss of chromosome Y promotes leukemogenesis and clonal hematopoiesis.
Zhang Q; Zhao L; Yang Y; Li S; Liu Y; Chen C
JCI Insight; 2022 Feb; 7(3):. PubMed ID: 35132955
[TBL] [Abstract][Full Text] [Related]
9. Acute Myeloid Leukemia and Myelodysplastic Syndromes with
Sill H; Zebisch A; Haase D
Clin Cancer Res; 2020 Oct; 26(20):5304-5309. PubMed ID: 32816950
[TBL] [Abstract][Full Text] [Related]
10. Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis.
Loberg MA; Bell RK; Goodwin LO; Eudy E; Miles LA; SanMiguel JM; Young K; Bergstrom DE; Levine RL; Schneider RK; Trowbridge JJ
Leukemia; 2019 Jul; 33(7):1635-1649. PubMed ID: 30692594
[TBL] [Abstract][Full Text] [Related]
11. Induction of the 5S RNP-Mdm2-p53 ribosomal stress pathway delays the initiation but fails to eradicate established murine acute myeloid leukemia.
Jaako P; Ugale A; Wahlestedt M; Velasco-Hernandez T; Cammenga J; Lindström MS; Bryder D
Leukemia; 2017 Jan; 31(1):213-221. PubMed ID: 27256803
[TBL] [Abstract][Full Text] [Related]
12. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.
Kojima K; Konopleva M; Samudio IJ; Shikami M; Cabreira-Hansen M; McQueen T; Ruvolo V; Tsao T; Zeng Z; Vassilev LT; Andreeff M
Blood; 2005 Nov; 106(9):3150-9. PubMed ID: 16014563
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.
Carvajal LA; Neriah DB; Senecal A; Benard L; Thiruthuvanathan V; Yatsenko T; Narayanagari SR; Wheat JC; Todorova TI; Mitchell K; Kenworthy C; Guerlavais V; Annis DA; Bartholdy B; Will B; Anampa JD; Mantzaris I; Aivado M; Singer RH; Coleman RA; Verma A; Steidl U
Sci Transl Med; 2018 Apr; 10(436):. PubMed ID: 29643228
[TBL] [Abstract][Full Text] [Related]
14. Cellular carcinogenesis in preleukemic conditions:drivers and defenses.
Ueda K; Ikeda K
Fukushima J Med Sci; 2024 Jan; 70(1):11-24. PubMed ID: 37952978
[TBL] [Abstract][Full Text] [Related]
15. Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy.
Maganti HB; Jrade H; Cafariello C; Manias Rothberg JL; Porter CJ; Yockell-Lelièvre J; Battaion HL; Khan ST; Howard JP; Li Y; Grzybowski AT; Sabri E; Ruthenburg AJ; Dilworth FJ; Perkins TJ; Sabloff M; Ito CY; Stanford WL
Cancer Discov; 2018 Nov; 8(11):1376-1389. PubMed ID: 30115703
[TBL] [Abstract][Full Text] [Related]
16. p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status.
Quintás-Cardama A; Hu C; Qutub A; Qiu YH; Zhang X; Post SM; Zhang N; Coombes K; Kornblau SM
Leukemia; 2017 Jun; 31(6):1296-1305. PubMed ID: 27885271
[TBL] [Abstract][Full Text] [Related]
17. Mice with a Mutation in the Mdm2 Gene That Interferes with MDM2/Ribosomal Protein Binding Develop a Defect in Erythropoiesis.
Kamio T; Gu BW; Olson TS; Zhang Y; Mason PJ; Bessler M
PLoS One; 2016; 11(4):e0152263. PubMed ID: 27042854
[TBL] [Abstract][Full Text] [Related]
18. Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies.
Ueda K
Exp Hematol; 2023 Jun; 122():10-18. PubMed ID: 37086813
[TBL] [Abstract][Full Text] [Related]
19. Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses.
Timofeev O; Klimovich B; Schneikert J; Wanzel M; Pavlakis E; Noll J; Mutlu S; Elmshäuser S; Nist A; Mernberger M; Lamp B; Wenig U; Brobeil A; Gattenlöhner S; Köhler K; Stiewe T
EMBO J; 2019 Oct; 38(20):e102096. PubMed ID: 31483066
[TBL] [Abstract][Full Text] [Related]
20. Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway.
Chen S; Wang Q; Yu H; Capitano ML; Vemula S; Nabinger SC; Gao R; Yao C; Kobayashi M; Geng Z; Fahey A; Henley D; Liu SZ; Barajas S; Cai W; Wolf ER; Ramdas B; Cai Z; Gao H; Luo N; Sun Y; Wong TN; Link DC; Liu Y; Boswell HS; Mayo LD; Huang G; Kapur R; Yoder MC; Broxmeyer HE; Gao Z; Liu Y
Nat Commun; 2019 Dec; 10(1):5649. PubMed ID: 31827082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
